Literature DB >> 27268085

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.

Alan K Burnett1, Nigel H Russell2, Robert K Hills1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27268085     DOI： 10.1182/blood-2016-04-712091

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Authors:  Steven Knapper; Nigel Russell; Amanda Gilkes; Robert K Hills; Rosemary E Gale; James D Cavenagh; Gail Jones; Lars Kjeldsen; Michael R Grunwald; Ian Thomas; Heiko Konig; Mark J Levis; Alan K Burnett
Journal:  Blood       Date:  2016-11-21       Impact factor: 22.113

Review 5.  Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.

Authors:  Carlos Best-Aguilera; O Rodrigo Gómez-Vázquez; A Elizabeth Guzmán-Hernández; R Monserrat Rojas-Sotelo
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

Review 6.  Gilteritinib: potent targeting of FLT3 mutations in AML.

Authors:  Mark Levis; Alexander E Perl
Journal:  Blood Adv       Date:  2020-03-24

7.  Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Stephen Knapper; Sylvie Freeman; Brian Huntly; Richard E Clark; Ian F Thomas; Lars Kjeldsen; Mary Frances McMullin; Mark Drummond; Jonathan Kell; Ruth Spearing
Journal:  J Clin Oncol       Date:  2020-12-23       Impact factor: 44.544

8.  Unified classification and risk-stratification in Acute Myeloid Leukemia.

Authors:  Nigel H Russell; Sean M Devlin; Brian J P Huntly; Elli Papaemmanuil; Yanis Tazi; Juan E Arango-Ossa; Yangyu Zhou; Elsa Bernard; Ian Thomas; Amanda Gilkes; Sylvie Freeman; Yoann Pradat; Sean J Johnson; Robert Hills; Richard Dillon; Max F Levine; Daniel Leongamornlert; Adam Butler; Arnold Ganser; Lars Bullinger; Konstanze Döhner; Oliver Ottmann; Richard Adams; Hartmut Döhner; Peter J Campbell; Alan K Burnett; Michael Dennis
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

Review 9.  FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.

Authors:  Naval Daver; Sangeetha Venugopal; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2021-05-27       Impact factor: 11.037

10.  Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?

Authors:  Shannon R McCurdy; Selina M Luger
Journal:  Haematologica       Date:  2021-10-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.